Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
| Previous Close | 5.730 |
| Open | 5.730 |
| Bid | 5.790 x N/A |
| Ask | 5.880 x N/A |
| Day's Range | 5.730 - 5.900 |
| 52 Week Range | 5.600 - 12.800 |
| Volume | |
| Avg. Volume | 228,168 |
| Market Cap | 2.33B |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Exploring High Growth Tech Stocks In Hong Kong
As global markets experience shifts with interest rate adjustments and economic indicators showing mixed signals, the Hong Kong market remains a focal point for investors seeking opportunities in high-growth tech sectors. In this dynamic environment, identifying promising stocks often involves assessing companies that not only demonstrate robust innovation and adaptability but also align well with prevailing market trends and economic conditions.
- Simply Wall St.
Top SEHK Growth Companies With High Insider Ownership In October 2024
As global markets experience varied economic shifts, with U.S. stocks reaching new highs and Chinese equities facing declines, the Hong Kong market remains a focal point for investors seeking growth opportunities amidst these fluctuations. In this context, identifying companies with high insider ownership can be particularly insightful, as such alignment often signals confidence in a company's potential to navigate current economic conditions effectively.
